Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Colorectal Cancer Drugs Market Forecast: What Value Will The Market Reach By 2030?
The colorectal cancer drugs market has shown consistent expansion in recent years. It is projected to grow from $21.72 billion in 2025 to $22.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.9%. This historical growth can be attributed to the increasing incidence of colorectal cancer, developments in chemotherapy drugs, heightened awareness of cancer screening, improvements in hospital infrastructure, and the availability of generic colorectal cancer drugs.
The colorectal cancer drugs market size is anticipated to experience substantial growth over the coming years. This market is projected to reach $28.57 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.8%. This projected expansion during the forecast period is driven by factors such as the rise of immunotherapy and targeted therapies, the incorporation of AI into drug development, increased adoption of precision medicine, enhanced oncology research funding, and an uptick in combination treatment regimens. Key developments anticipated in the forecast period encompass personalized cancer treatments, advancements in immunotherapy, specific molecular therapies, improved early detection and screening methods, and diversified combination therapy strategies.
Get A Free Sample Report With In-Depth Market Insights:
Colorectal Cancer Drugs Market Growth Momentum: What Factors Are Shaping Demand?
The escalating need for personalized medicines is anticipated to stimulate the future growth of the colorectal cancer drugs market. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that accounts for individual differences in patients’ genes, environments, and lifestyles. This strategy is revolutionizing the treatment of CRC, providing more tailored and efficacious care for patients. It is expected to continue driving the expansion of the CRC drug market as research and drug development initiatives become increasingly customized to specific genetic and molecular profiles. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA gave its approval to 16 new personalized therapies for rare disease patients in 2023, representing a significant rise from the six approved in 2022. Consequently, the rising demand for personalized medicine is a key driver of growth for the colorectal cancer drugs market.
Colorectal Cancer Drugs Market Segment Analysis Spotlighting Growth Areas
The colorectal cancer drugs market covered in this report is segmented –
1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, BRAF Or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators
2) By Class: Immunotherapy, Chemotherapy, Other Classes
3) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab, Ramucirumab, Other VEGF Inhibitors
2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab, Panitumumab, Other EGFR Inhibitors
3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab, Nivolumab, Other PD1 Or PDL1 Inhibitors
4) By BRAF Or MEK Inhibitors: Vemurafenib, Encorafenib, Trametinib, Other BRAF Or MEK Inhibitors
5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib, Sorafenib, Other TKI Inhibitors
6) By Immunomodulators: Checkpoint Inhibitors, Other Immunomodulating Agents
Colorectal Cancer Drugs Market Trends Redefining Industry Growth
Leading companies operating within the colorectal cancer drugs market are securing FDA approvals for novel medications, such as LONSURF (trifluridine/tipiracil), to enhance their profitability in the sector. LONSURF (trifluridine/tipiracil) is an orally administered, prescription-only drug utilized in the treatment of specific cancers, including colon, rectal, and stomach cancer that has metastasized to other areas of the body. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, announced that the Food and Drug Administration had approved the combination of LONSURF (trifluridine/tipiracil) with bevacizumab for managing metastatic colorectal cancer (mCRC) in adult patients. Compared to LONSURF administered alone, the combination of LONSURF with bevacizumab considerably improved both overall survival (OS) and progression-free survival (PFS). With a hazard ratio of 0.61 (95% CI: 0.49, 0.77, 1-sided p0.001), the median OS was recorded as 10.8 months in the LONSURF + bevacizumab arm, contrasting with 7.5 months in the LONSURF arm.
Colorectal Cancer Drugs Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the colorectal cancer drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Servier Laboratories, Eisai Co. Ltd., Taiho Pharmaceutical Co. Ltd., Taiho Oncology Inc., Daiichi Sankyo Company Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.
View The Full Colorectal Cancer Drugs Market Report:
Colorectal Cancer Drugs Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the colorectal cancer drugs market in 2025. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model